abstract: OBJECTIVE: Although numerous studies have demonstrated the effectiveness of both individual and group cognitive-behavioral psychotherapy (CBT), many authors have questioned the translation of these interventions into routine clinical practice. The aim of this study was to assess the effectiveness of group CBT in @entity1 diagnosed with @entity4697 , with or without @entity8396 , in routine clinical practice. METHODS: The study involved 96 @entity1 diagnosed according to the DSM-IV criteria. Treatment consisted of 10 psychotherapy sessions of 2 hours each in a local health authority. A battery of psychometric instruments was used to assess variables including psychological symptoms, subjective well-being and psychosocial functioning before and after therapy. In addition to the evaluation of treatment outcome, final scores were compared to population norms and benchmarked against similar studies. RESULT: Almost all scores of the clinical scales used improved significantly. Only 42% of @entity1 who were initially above the clinical cut-off on the CORE-OM showed clinically significant changes, and 20% of @entity1 were below the clinical cut-off after treatment. Post-treatment CORE-OM scores were not significantly different from the values observed in the general population. These findings are consistent with those of comparable studies. DISCUSSION: Group CBT is effective in routine clinical practice. In addition to reducing @entity148 , treatment also results in an improvement of other related variables such as subjective well-being. Owing to its better @entity1 -therapist ratio, group CBT should be considered as an alternative to individual CBT in routine clinical care in public services.

title: [Group cognitive-behavioral therapy for @entity4697 with and without XXXX : an effectiveness study].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity8396 :: ('MESH:D000379', 'Disease') :: ['agoraphobia']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety symptoms']

entities_list: @entity4697 :: ('MESH:D016584', 'Disease') :: ['panic disorder']

answer: @entity8396 :: (MESH:D000379,Disease) :: ['agoraphobia']


abstract: The addition of @entity1063 , @entity1425 , or @entity1928 to collagenase-dispersed @entity35 liver hepatocytes increase @entity268 and result in a 15% loss in total cell @entity1025 within 5 min. Conversely, @entity5402 and @entity1951 induce @entity35 -15% increase of total cell @entity1025 . Permeabilized hepatocytes also mobilize a large pool of @entity1025 when stimulated by @entity857 or @entity268 . This stimulation is completely inhibited by @entity27605 and @entity24948 , two different specific inhibitors of the mitochondrial @entity1708 translocase. @entity268 directly mobilizes @entity1025 efflux from isolated @entity35 liver mitochondria. 50 nM @entity268 or 250 microM @entity857 induces in 5 min a mitochondrial loss of about 6 nmol of @entity1025 /mg of protein and a stimulation of @entity855 efflux. The effect of @entity268 is specific, is not reproduced by other cyclic or noncyclic @entity2036 , and is inhibited by inhibitors of the @entity1708 translocase. These data indicate that @entity268 is a messenger for a major mobilization of @entity1025 in hepatocytes. A major target for the effect of @entity268 are mitochondria, which lose up to 20-25% of their total @entity1025 in 5 min, both within the cell and after isolation. Evidence is presented suggesting that the @entity1708 translocase is the target of the @entity268 -dependent @entity1025 efflux and that @entity268 may change the operation of the translocase. This, in turn, could change within the matrix the substrate of choice of the translocase from @entity855 to @entity855 .Mg.

title: Cyclic AMP-induced @entity1025 release from XXXX liver hepatocytes, permeabilized hepatocytes, and isolated mitochondria.

entities_list: @entity1708 :: ('CHEBI:61293', 'Chemical') :: ['adenine nucleotide']

entities_list: @entity27605 :: ('MESH:D001278', 'Chemical') :: ['atractyloside']

entities_list: @entity2036 :: ('MESH:D009711', 'Chemical') :: ['nucleotides']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity1951 :: ('MESH:D014667', 'Chemical') :: ['vasopressin']

entities_list: @entity24948 :: ('MESH:D001865', 'Chemical') :: ['bongkrekic acid']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbachol']

entities_list: @entity1928 :: ('MESH:D005576', 'Chemical') :: ['forskolin']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: The diagnosis of @entity210 in the intercritical phase can be difficult. OBJECTIVE: To determine whether synovial fluid analysis allows the diagnosis of @entity210 . DESIGN: Cross-sectional study. SETTING: Outpatient rheumatology clinics. @entity1 : 101 @entity1 with @entity210 . INTERVENTION: Arthrocentesis of 80 knees and 21 first @entity2720 (each joint from a different @entity1 ) that had been inflamed but were currently asymptomatic. MEASUREMENTS: Frequency with which arthrocentesis yielded synovial fluid; presence of @entity414 crystals in the synovial fluid sample; and, for synovial fluid with crystals, the number of microscope fields that had to be scanned before crystals were found. RESULTS: Synovial fluid was obtained from 91 of 101 joints. The fluid from all 43 @entity1 not receiving hypouricemic agents contained @entity414 crystals. These crystals were found in the synovial fluid of only 34 of 48 @entity1 receiving hypouricemic agents. In 90% of the synovial fluid samples that contained crystals, crystals were seen in the first five microscope fields examined. CONCLUSIONS: Arthrocentesis of asymptomatic knees and first @entity2720 and synovial fluid analysis are simple procedures that facilitate the diagnosis of @entity210 during intercritical periods.

title: Synovial fluid analysis for diagnosis of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity210 :: ('MESH:D006073', 'Disease') :: ['gout', 'intercritical gout']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['metatarsophalangeal joints']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['monosodium urate']

answer: @entity210 :: (MESH:D006073,Disease) :: ['intercritical gout']


abstract: BACKGROUND: Withdrawal of @entity205 -A from maintenance immunosuppressive therapy involves risk of rejection. The aim of the study was to reduce the risk of rejection and to evaluate the @entity400 in predicting rejection. METHODS AND RESULTS: In 41 @entity1 14.4 +/- 2.6 months after the first transplantation of a cadaveric graft with good and stabilized function, @entity205 was withdrawn from triple-drug therapy while the doses of @entity500 and @entity229 were increased. Prior to the change @entity400 ( @entity400 ) was performed and @entity1667 500-250-250 mg administered in 3 days. @entity400 was repeated after 2 weeks. 39 @entity1 fulfilling inclusion criteria but ineligible for the switch for different reasons served as a control group. Both groups were comparable in demographic and immunological parameters. Within 3 months after conversion, rejection was observed in 3 @entity1 (7%) vs 2 @entity1 (5%) of the control group over a comparable period of time: and within 6 months in 6 @entity1 (15%) and 3 @entity1 (8%) respectively (NS). No relationship between rejections before and after conversion was found. @entity400 appeared to have some predictive value for rejection. In all of the 3 @entity1 experiencing rejection, a rejection pattern was present in the 2nd biopsy. CONCLUSIONS: Incorporation of @entity1667 into conversion therapeutic regime decreased the risk of rejection to 7%. The rejection pattern in the second @entity400 after @entity1667 administration may be predictive for further rejection development.

title: [Conversion of XXXX therapy to conventional treatment with diagnostic use of aspiration biopsy in kidney transplantation].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine', 'cyclosporin']

entities_list: @entity400 :: ('MESH:D014202', 'Disease') :: ['fine-needle aspiration biopsy', 'FNAB']

answer: @entity205 :: (MESH:D016572,Chemical) :: ['cyclosporin A']


abstract: @entity844 binding proteins (FABPs) carry @entity1718 (FAs) and other lipids in the cellular environment, and are thus involved in processes such as FA uptake, transport, and oxidation. These proteins bind either one or two ligands in a binding site, which appears to be inaccessible from the bulk. Thus, the entry of the substrate necessitates a conformational change, whose nature is still unknown. A possible description of the ligand binding process is given by the portal hypothesis, which suggests that the FA enters the protein through a dynamic area known as the portal region. On the other hand, recent simulations of the @entity5548 ( @entity5548 ) suggested a different entry site (the alternative portal). In this article, we discuss molecular dynamics simulations of the apo-intestinal-FABP ( @entity1630 ) in the presence of @entity2365 molecule(s) in the simulation box. The simulations were carried out to study whether the FA can enter the protein during the simulations (as in the @entity5548 ) and where the ligand entry site is (the portal region, the alternative portal or a different domain). The analysis of the simulations revealed a clear difference between the @entity5548 and the @entity1630 . In the latter case, the @entity2365 preferentially adsorbed to the portal region, which was more mobile than the rest of the protein. However, no ligand entry was observed in the multi-nanosecond-long simulations, in contrast to @entity5548 . These findings suggest that, although the main structural motif of the FABPs is common, the fine details of each individual protein structure grossly modulate its reactivity.

title: @entity844 binding proteins: same structure but different binding mechanisms? Molecular dynamics simulations of intestinal XXXX binding protein.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['Fatty acid']

entities_list: @entity2365 :: ('CHEBI:7896', 'Chemical') :: ['palmitate']

entities_list: @entity5548 :: ('2167', 'Gene') :: ['adipocyte lipid binding protein', 'ALBP']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity844 :: (CHEBI:35366,Chemical) :: ['fatty acid']


abstract: A case of @entity5 following radiotherapy for @entity977 is presented in detail with a review of the literature. A 38 year-old housewife had developed a @entity2124 secreting @entity977 , and received a total of 50 Gy at the pituitary region. Four years and six months later, she began suffering @entity10 and @entity391 . Computed tomography showed an extensive low density with ring enhancement in the right temporal region, corresponding to the previously irradiated field. A right frontotemporoparietal craniotomy was carried out, and a soft and reddish @entity5 was partially removed. The histological diagnosis was that of @entity5 . The @entity1 was submitted to postoperative radiochemotherapy, receiving a total of 60 Gy, @entity19911 ( @entity4175 ), and tegafur (FT). Subsequently, after three months of clinical relief, she developed @entity5 regrowth, and died four months later. The present case fulfills the criteria for radiation-induced @entity5 established by Cahan et al.: A @entity5 location within irradiated area, no evidence of @entity5 prior to radiotherapy, a long latency period between radiation and @entity5 occurrence, and histological verification of the @entity5 . Thirty-nine cases of radiation-induced @entity11 including the present case have been reported in the literature. It is noteworthy that the majority occur in the younger age bracket. Male preponderance is noted as it is in primary @entity13 . The primary lesions for radiation frequently include @entity1778 and @entity706 . @entity976 , @entity977 , and @entity2946 etc are also included.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Malignant astrocytoma following radiotherapy in XXXX : case report].

entities_list: @entity13 :: ('MESH:C564230', 'Disease') :: ['cerebral gliomas']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant astrocytoma']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas']

entities_list: @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenoma']

entities_list: @entity976 :: ('MESH:D003397', 'Disease') :: ['Craniopharyngioma']

entities_list: @entity19911 :: ('CHEBI:7576', 'Chemical') :: ['nimustine hydrochloride']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity2946 :: ('MESH:D008527', 'Disease') :: ['medulloblastoma']

answer: @entity977 :: (MESH:D010911,Disease) :: ['pituitary adenoma']


abstract: With use of porous-coated implants, total hip arthroplasty was performed in a consecutive series of thirty @entity1 (thirty-five hips) who had a preoperative diagnosis of late-stage (Ficat and Arlet stage-III or IV) @entity2530 of the femoral head. The @entity1 were evaluated clinically and radiographically, and the data were recorded in a prospective manner. The average duration of follow-up was seven and one-half years (range, five to ten years). The average age of the @entity1 at the time of the operation was thirty-two years (range, twenty-one to forty years). Signs of osseointegration of the femoral stem to the host bone were demonstrated in thirty-three hips (94 per cent). In the porous-coated hemispherical acetabular cups of these hips, an optimum bone-implant interface was identified and maintained, suggesting @entity79 . The rate of revision was 3 per cent (one hip) for the femoral side and 6 per cent (two hips) for the acetabular side, for an over-all rate of 6 per cent. All @entity1 maintained a high level of activity postoperatively. There was moderate or severe @entity5707 of proximal femoral resorptive bone and stress-shielding in six hips (17 per cent) and osteolytic reactions in six hips. Complications were frequent (six hips) and included one @entity281 ; two dislocations; two instances of @entity2736 ; and one @entity174 of the calcar femorale, which occurred intraoperatively. The thirty @entity1 had a lower rate of revision and improved clinical outcomes compared with other reported series of young @entity1 managed with total hip arthroplasty with cement who had the same diagnosis and similar postoperative follow-up. However, the latter series involved implants of an earlier design that had been inserted with older techniques of cementing. When arthroplasty is considered for the treatment of late-stage @entity2530 of the femoral head in young @entity1 , the use of total hip implants without cement that allow for @entity79 appears to be a viable alternative to arthroplasty with use of cement. However, longer follow-up is needed to determine the outcome of the osteolytic reactions that we observed. We therefore recommend this procedure with some caution because of the high rate of complications and the potential for failure of the arthroplasty related to the osteolytic reactions.

title: XXXX of the femoral head treated with total hip arthroplasty without cement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone ingrowth']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['deep infection']

entities_list: @entity5707 :: ('MESH:D020257', 'Disease') :: ['remodeling']

entities_list: @entity2736 :: ('MESH:D009999', 'Disease') :: ['heterotopic ossification']

entities_list: @entity2530 :: ('MESH:D010020', 'Disease') :: ['osteonecrosis']

answer: @entity2530 :: (MESH:D010020,Disease) :: ['Osteonecrosis']


abstract: BACKGROUND: Despite successful reperfusion therapy of @entity583 and complete restoration of @entity1188 patency, the improvement of systolic function in long-term outcome depends on preserved microvasculature integrity. Myocardial contrast echocardiography (MCE) is a useful technique for identification of viable myocardium. AIM: To assess the value of real-time myocardial contrast echocardiography (rt-MCE) in prediction of left ventricular function improvement in @entity1 with anterior wall @entity583 as well as selection of the optimal cut-off value for the number of dysfunctional segments with preserved complete perfusion, in order to predict the global left ventricular function improvement during one-month observation. METHODS: Rt-MCE was performed in 74 @entity1 (50 @entity1 , aged 58+/-11 years) with anterior wall @entity583 , treated with primary percutaneous coronary intervention (PCI) within 12 hours from the onset of symptoms. After estimation of regional contractility disturbances and global systolic function of the left ventricle, rt-MCE was performed with contrast assessment of dysfunctional segments (normal contrast pattern=2, heterogeneous=1, lack of contrast=0). Regional perfusion score index (RPSI) was calculated by adding the perfusion indices and dividing by the number of dysfunctional segments. RESULTS: Of a total of 1184 visualised segments, 344 (29.1%) were dysfunctional (189 @entity5048 , 155 @entity2845 ). Contractility improvement was observed in 192 segments (preserved viability in 105 @entity5048 and 37 @entity2845 segments). In a group of 44 @entity1 with systolic function improvement, 34 of them had preserved viability, and in a group of 30 @entity1 without LVEF improvement, in 22 of them myocardium viability was not observed. Sensitivity, specificity and accuracy of rt-MCE in prediction of left ventricular global improvement were 72.7%, 73.3% and 73%, respectively, whereas in prediction of regional function improvement these values were 73.9%, 77% and 75.5%, respectively. CONCLUSION: Rt-MCE performed in the early phase of @entity583 enables the prediction of left ventricular regional and global function improvement in @entity1 treated with primary PCI.

title: The use of myocardial contrast echocardiography in the assessment of left ventricular function recovery after primary percutaneous coronary intervention in the setting of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity5048 :: ('MESH:C536231', 'Disease') :: ['hypokinetic']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct-related artery']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: BACKGROUND: Members of the @entity645 / @entity791 community are known to use web-based tools to support learning about treatment issues. Initial research indicated components such as message forums or web-based documentation were effectively used by @entity1 with @entity645 / @entity791 . Video has also shown promise as a technology to aid consumer health education. However, no research has been published thus far investigating the impact of web-based environments combining these components in an educational workshop format. METHODS: In this qualitative study @entity645 / @entity791 community members provided feedback on an integrated web-based consumer health education environment. @entity1 were recruited through organizations that serve the @entity645 / @entity791 community located in Toronto, Canada. Demographics, data on Internet use, including messages exchanged in the study environment were collected. A group interview provided feedback on usability of the study environment, preferences for information formats, use of the message forum, and other sources for learning about treatment information. RESULTS: In this pilot study analysis of the posted messages did not demonstrate use for learning of the workshop content. @entity1 did not generally find the environment of value for learning about treatment information. However, @entity1 did share how they were meeting these needs. It was indicated that a combination of resources are being used to find and discuss treatment information, including in- @entity1 sources. CONCLUSION: More research on the ways in which treatment information needs are being met by @entity645 / @entity791 community members and how technology fits in this process is necessary before investing large amounts of money into web-based interventions. Although this study had a limited number of @entity1 , the findings were unexpected and, therefore, of interest to those who intend to implement online consumer health education initiatives or interventions.

title: Consumer e-health education in XXXX / @entity791 : a pilot study of a web-based video workshop.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'person', 'persons']

answer: @entity645 :: (57667,Species) :: ['HIV']


abstract: OBJECTIVE: To determine prevalence of foot lesions, @entity1909 , @entity75 , @entity854 , and @entity75 , and body condition scores among culled female @entity1707 at slaughter. DESIGN: Observational study. ANIMALS: Culled gilts and sows killed during a 1-week period at a Midwest slaughterhouse. PROCEDURE: Carcasses were examined, and lesions were recorded. Body condition was scored on the basis of standard criteria. RESULTS: 58.9% (1,029/1,747) of the carcasses had foot lesions, 67.3% (1,178/1,751) had @entity1909 , and 4.6% (80/1,751) had @entity75 . Body condition score was significantly associated with detection of @entity1909 and @entity75 . Mean +/- SE number of teats (n = 1,432 carcasses) was 13.86 +/- 0.02. Mean numbers of normal-appearing teats in the left and right mammary chains were 6.57 +/- 0.02 and 6.58 +/- 0.02, respectively. Feet from 48% (688/1,433) of the carcasses were condemned. @entity75 were found in 48.8% (624/1,278) of the carcasses; of the carcasses with lesions, 412 (66%) had @entity409 , and 268 (42.9%) had @entity55 . CLINICAL IMPLICATIONS: Lesions that potentially could have adversely affected production were found in a large percentage of culled gilts and sows at slaughter. Knowledge of lesions commonly found at slaughter may help direct changes in herd health programs.

title: Prevalence of lesions and body condition scores among female XXXX at slaughter.

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Visceral lesions', 'visceral lesions', 'shoulder lesions']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver spots']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['mammary gland abnormalities']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

answer: @entity1707 :: (9823,Species) :: ['swine']


abstract: Analysis was made to determine concentrations of @entity33910 ( @entity11984 ) in maternal serum, and intrauterine tissues of myometrium, placenta, fetal membrane, amniotic fluid and fetal lung after one shot intravenous infusion of 100 mg of @entity11984 to @entity95 with 25th day-pregnancy, and the following results were obtained. 1. Concentrations of @entity11984 in maternal serum, myometrium and placenta reached their maximum levels in 30 minutes after administration, then decreased rapidly. 2. The concentration of @entity11984 in the fetal membrane reached its maximum level in 30 to 60 minutes after the administration, then it decreased to a nearly constant level. 3. The concentration of @entity11984 in the amniotic fluid showed its maximum level in 30 minutes after administration, then decreased, but somewhat increased again thereafter. 4. The concentration of @entity11984 in the fetal lung was elevated gradually after administration, then decreased after reaching its maximum level at 90 minutes, after administration to a nearly constant level. It was deemed, however, that higher concentrations would be necessary to achieve therapeutic effects because attained concentrations were lower than those in other tissues.

title: [A study of tissue transfer of @entity33910 in the blood and uterus in pregnant XXXX ].

entities_list: @entity33910 :: ('MESH:D015311', 'Chemical') :: ['cefmetazole']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: The evaluation of the degree of reduction in the cross-sectional area of an artery has important pathophysiologic and therapeutic implications. Currently, no technique can easily provide this information. In this in vitro study we evaluated the potential of a new imaging technique, intravascular high frequency ultrasound angioscopy, in the estimation of percentage of cross-sectional area @entity850 of an artery. To do this, we compared intravascular high frequency ultrasound to previously-validated external high frequency ultrasound and to anatomic estimation of @entity2791 . Using a prototype intraluminal imaging catheter with a 20 MHz ultrasound transducer at its tip, we imaged 20 arterial segments of various size (15 to 90 mm2 lumen area by anatomy) in the control state and after experimental @entity850 . These arterial segments were also imaged by external high frequency ultrasound. Lumen areas were measured from calibrated ultrasound images in the control state and after @entity850 , and percentage of cross-sectional area @entity850 was calculated. These data were compared to the percentage of area @entity850 derived from calibrated anatomic photographs of the arteries taken in the control state and after @entity850 . Both intravascular ultrasound angioscopy and external high frequency ultrasound yielded high-resolution, two-dimensional, circumferential images of the arteries. Alterations in vessel area and shape were apparent after creation of @entity850 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Intravascular ultrasound estimation of XXXX .

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity2791 :: ('MESH:D012078', 'Disease') :: ['arterial stenosis']

answer: @entity2791 :: (MESH:D012078,Disease) :: ['arterial stenosis']


abstract: A Bacillus sp. CCMI 966, characterised as @entity3881 , has a duplication time of about 24 min. It produces at least two extracellular xylanases, Xyl I and Xyl II. The extracellular xylanase activity seems to be strongly correlated with the biomass growth profile. The Xyl II isoenzyme was purified by @entity4859 precipitation and anionic exchange chromatography, with a purification factor of 8.3. The molecular weight of the isoenzyme was estimated by @entity214 -PAGE revealing that Xyl II is a multimeric enzyme with a catalytic subunit of about 20 kDa. Under non-denaturing conditions, a molecular weight of about 340 kDa was obtained by native PAGE gel and of 20 kDa by gel filtration chromatography. The enzyme showed an optimum pH and temperature of 6.0 at 60 degrees C. Xyl II was stable at 40 degrees C for 180 min at pH 6.0. The specificity of Xyl II for different substrates was evaluated. Xyl II presents a higher affinity towards OSX, with a K(m) of 1.56 g l(-1) and showed the ability to hydrolyse @entity26538 , with a K(m) of 1.02 g l(-1). @entity46308 is the main product of xylan degradation. The Xyl II ability for binding to cellulose and/or xylan was also studied.

title: Enzymatic properties of a neutral endo-1,3(4)-beta-xylanase Xyl II from XXXX .

entities_list: @entity46308 :: ('CHEBI:62972', 'Chemical') :: ['Xylotetraose']

entities_list: @entity4859 :: ('CHEBI:62946', 'Chemical') :: ['ammonium sulphate']

entities_list: @entity26538 :: ('MESH:C008247', 'Chemical') :: ['laminarin']

entities_list: @entity3881 :: ('1423', 'Species') :: ['Bacillus subtilis']

answer: @entity3881 :: (1423,Species) :: ['Bacillus subtilis']


abstract: Vaccinations in pregnancy are an important aspect of prenatal care and of improving not only maternal health but also neonatal outcomes. Only 2 vaccines are specifically recommended during pregnancy: @entity683 and @entity116 , diphtheria, and acellular pertussis (Tdap). Because @entity683 disproportionately affects pregnant @entity1 compared with other populations, annual prevention of @entity683 is recommended for all @entity1 who will be pregnant during @entity683 season (October to May). Influenza vaccination has been recently reported to also result in decreased febrile respiratory illnesses in the newborn, likely through passive antibody transfer. @entity281 rates are rising in the United States as vaccine-induced immunity wanes, with the mortality burden primarily seen in @entity1 aged <6 months. Pertussis immunization with Tdap is now recommended for all pregnant @entity1 during the late second (>20 weeks) or third trimester with the intent to both protect the pregnant @entity1 and provide passive antibody to the @entity1 before vaccination at 2 months of age. Provider support for these recommendations regarding both annual @entity683 vaccination and postpartum Tdap vaccination during pregnancy is critical to ensuring vaccine delivery and improving both maternal and fetal health. The article reviews the epidemiology and clinical aspects of @entity683 and @entity281 with particular attention to pregnancy and recommendations for vaccination in these @entity1 . TARGET AUDIENCE: Obstetricians and gynecologists, ophthalmologists, neurologists, family physicians, emergency room physicians LEARNING OBJECTIVES: After completing this CME activity, obstetricians and gynecologists should be better able to analyze how @entity281 disproportionally affects pregnant @entity1 . Assess how @entity683 vaccination improves maternal and likely neonatal outcomes. Evaluate @entity281 and immunity in adults, and counsel pregnant @entity1 as to the benefits of Tdap vaccination, particularly for the @entity1 .

title: Influenza and XXXX , diphtheria, and acellular pertussis vaccinations during pregnancy.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'infants', 'infant']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza', 'influenza illness']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Pertussis infection', 'influenza infection', 'pertussis infection']

answer: @entity116 :: (MESH:D013746,Disease) :: ['tetanus']


abstract: Factors associated with clinician assessment may play a role in the increasing rate of failed trials. The use of centralized raters, a small group of highly skilled, tightly calibrated, and continuously monitored raters linked to the study sites through videoconferencing can address these issues by reducing the sheer number of raters involved, using rigorous calibration procedures not logistically feasible with a larger dispersed group of raters, and by blinding raters to visit and protocol. This phase 2 study was the first randomized controlled trial to use centralized raters in a study of treatments for @entity161 . Subjects (N = 313) from 32 sites were randomly assigned to 6 weeks of treatment with 1 of 2 doses of an investigational antipsychotic, @entity1037 15 mg, or placebo. Subjects were evaluated weekly using the Positive and Negative Syndrome Scale. Data from the @entity1037 (n = 68) and placebo (n = 68) arms were provided by the sponsor. The mean Positive and Negative Syndrome Scale change was significantly greater with @entity1037 (-15.2) than placebo (-4.43), P = 0.002. The significant difference was apparent at week 1. The effect size was 0.48. Internal consistency was high throughout the study. Scores at screening were normally distributed and not skewed toward the cutoff score. Results found that hospitalized @entity1 with @entity161 were willing and able to participate in clinical trials using remote interviews conducted via videoconference. This methodology shows enormous promise for use in clinical trials, even with acutely @entity716 @entity1 .

title: Use of remote centralized raters via live 2-way video in a multicenter clinical trial for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: PURPOSE: The objective of this study was to evaluate multiple morphological features on MR images in @entity1 with and without @entity397 to evaluate whether there are certain variables that confer a higher risk for an @entity397 . METHODS: MRI measurements were taken from 45 subjects with @entity130 and 43 subjects without @entity130 , by two independent observers. The morphometrics were compared between ACL-injured and non-injured subjects, between @entity1 and @entity1 and for male and female subjects separately. A factor analysis was performed to determine whether any variables were related in the injured, non-injured, male or female groups. RESULTS: There were no significant differences in the overall population between the ACL-injured and non-injured group. Significant differences were found in bicondylar (P   <=  0.001), medial condyle (P   <=  0.001) and lateral condyle widths (P  =  0.001) between @entity1 and @entity1 . In the male group, there were no significant differences between ACL-injured and non-injured subjects. In the female group, there was a significant difference in bicondylar (P  =  0.002) and lateral condyle width (P  =  0.002) between ACL-injured and non-injured subjects. CONCLUSIONS: There were gender-related differences in bony morphology between ACL-injured and non-injured subjects. The morphological features that were different between ACL-injured and non-injured subjects varied between male and female subjects. LEVEL OF EVIDENCE: Case-Control study, Level III.

title: Knee morphology and risk factors for developing an anterior cruciate XXXX : an MRI comparison between ACL-ruptured and non-injured knees.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ACL rupture']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['ACL injury']

answer: @entity397 :: (MESH:D012421,Disease) :: ['ligament rupture']


abstract: BACKGROUND: Regular, inhaled @entity2263 agonists may increase airway responsiveness in @entity748 subjects. The mechanism is not known but may be via an increase in @entity32 . A study was undertaken to examine the effect of regular inhaled @entity3045 on airway responsiveness to @entity2710 and hypertonic saline, on the maximal response plateau to @entity2710 , and on inflammatory cells in induced sputum in rhinitic non- @entity748 subjects. METHODS: Thirty subjects with a baseline maximal response plateau of > 15% fall in forced expiratory volume in one second (FEV1) entered a randomised, placebo controlled, parallel trial consisting of two weeks run in, four weeks of treatment, and two weeks washout. @entity2710 challenges were performed at the beginning of the run in period, before treatment, after treatment, and after washout. Hypertonic saline challenges were performed before and after treatment and induced sputum samples were collected for differential cell counting. RESULTS: There was no change in airway responsiveness, maximal response plateau to @entity2710 , or in induced sputum eosinophils or mast cells. The maximum fall in FEV1 after hypertonic saline increased in the @entity3045 group (median change 6.0%, interquartile range (IQR) 11.0) but did not change in the placebo group (median change 1.3%, IQR 5.5). CONCLUSIONS: Regular inhaled @entity3045 for four weeks increases airway responsiveness to hypertonic saline but does not alter airway responsiveness to @entity2710 or cells in induced sputum in non- @entity748 individuals with @entity2490 . The relevance of these findings to @entity748 subjects has not been established.

title: Effect of regular inhaled @entity3045 on airway responsiveness and @entity32 in rhinitic non- XXXX subjects.

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['airway inflammation']

entities_list: @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol']

entities_list: @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine', 'Methacholine']

answer: @entity748 :: (MESH:D013224,Disease) :: ['asthmatic']


abstract: Pulmonary thromboendarterectomy was performed on two @entity1 with @entity1151 showing @entity715 tendency. @entity1 1 was a 25-year-old male with the disease complicated by congenital @entity10647 . @entity1 2 was a 21-year-old male with the disease complicated by @entity1701 . Both @entity1 were admitted to the center upon showing @entity1353 . Lung perfusion scintigraphy revealed @entity156 in the right and left lungs. Pulmonary arteriography showed occlusion and @entity850 from lobar to segmental arteries. Cardiac catheterization showed marked @entity120 . Pulmonary angioscopy confirmed the presence of organized thrombi while an intravascular ultrasound revealed a thickening of the pulmonary arterial walls in both lungs. After the insertion of an inferior vena cava filter in each @entity1 , surgery was performed. Following a median sternotomy, a cardiopulmonary bypass was utilized to induce deep @entity2332 at a pharyngeal temperature of 16 degrees C, after which a thromboendarterectomy of the bilateral pulmonary arteries was performed under intermittent circulatory arrest. A large amount of organized thrombi was extracted from these arteries. After surgery, both @entity1 showed good postoperative outcome with improved blood flow in both lungs, @entity551 and increased cardiac output.

title: Chronic pulmonary thromboendarterectomy complicated by @entity10647 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity10647 :: ('MESH:D020152', 'Disease') :: ['antithrombin III deficiency']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity156 :: ('MESH:D000015', 'Disease') :: ['multiple defects']

entities_list: @entity1701 :: ('MESH:D016736', 'Disease') :: ['antiphospholipid syndrome']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['chronic pulmonary thromboembolism']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['reduced pulmonary arterial pressure']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

answer: @entity1701 :: (MESH:D016736,Disease) :: ['antiphospholipid syndrome']


abstract: BACKGROUND: Familial autoimmune @entity1737 ( @entity1737 ) is rare, although a genetic role for the development of @entity6107 is suggested by concordance in monozygotic twins and the increased frequency of other @entity792 in family members of myasthenics. METHODS: A @entity1 with a family history of @entity1737 was evaluated in hospital. Relatives were interviewed and medical records examined for details regarding the diagnosis of @entity1737 in three other family members. RESULTS: The index case first experienced symptoms of @entity1737 at age 75 years. She developed generalized @entity1737 and required corticosteroids and immunosuppressive therapy to control her disease. Her father developed predominantly bulbar symptoms of @entity1737 at age 75 years. He died of complications experienced following a gastrostomy placed for continued @entity4764 swallowing. His brother developed similar symptoms of @entity1737 in his early 60s and died shortly after thymectomy. A 46-year-old nephew of the index case is also beginning to exhibit signs of generalized @entity1737 . @entity934 receptor antibodies were strongly positive in the index case and her nephew. (The assay was not available for her father and uncle). CONCLUSIONS: Four individuals in three successive generations had diagnoses of @entity6107 . Study of familial cases such as these may clarify the contribution of genetic factors to the development of this disease.

title: XXXX : four @entity1 involving three generations.

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['MG', 'myasthenia gravis']

entities_list: @entity6107 :: ('MESH:D020720', 'Disease') :: ['autoimmune MG']

entities_list: @entity4764 :: ('MESH:D051346', 'Disease') :: ['difficulty']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['Acetylcholine']

answer: @entity792 :: (MESH:D001327,Disease) :: ['Familial autoimmune myastenia gravis']


abstract: @entity1548 , as well as @entity2520 , seems to have cyclic patterns of evolution. Periods of burst may be intercalated with periods of quiescence. Because keratinocyte division must occur during cyst growth, it is presumed that epithelium status could indicate the biological activity of @entity9530 ( @entity9530 ). @entity1198 and Th2 are important heterogeneous stages of lymphocyte differentiation. @entity56 immune reactions are mediated by @entity1198 lymphocytes, whereas Th2 populations mediate some types of humoral immune response. Th2 lymphocytes are characterized by high expression of @entity5823 glycoprotein. @entity1198 and Th2 lymphocytes have not been evaluated in periapical inflammatory lesions. The purpose of this study was to evaluate @entity5823 + cells in @entity9530 with @entity3202 and @entity5072 epithelium. A @entity1885 -streptavidin amplified system was used for identification of @entity5823 receptor. Results demonstrate increased proportions of Th2 cells in cysts with @entity5072 epithelium. Our results suggest that Th2 cells could be associated with RC growth.

title: Immunohistochemical study of XXXX .

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity5072 :: ('MESH:D000796', 'Disease') :: ['hyperplastic']

entities_list: @entity1548 :: ('MESH:D010483', 'Disease') :: ['Periapical lesions']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['Delayed-type hypersensitivity']

entities_list: @entity9530 :: ('MESH:D011842', 'Disease') :: ['RCs', 'radicular cysts']

answer: @entity9530 :: (MESH:D011842,Disease) :: ['apical periodontal cysts']


abstract: The pivotal role of @entity6006 for mesangioproliferative @entity8 is well established. Here, @entity25536 ( @entity25536 ) was identified as a downstream signaling target of @entity6006 . In healthy kidney cells, @entity25536 was located predominantly within the nuclear compartment. Subsequent to @entity6006 infusion and in the course of anti-Thy1.1-induced mesangioproliferative @entity631 , relocalization of @entity25536 into the cytoplasm was observed. In experimental models that lack profound mesangial cell proliferation (e.g., @entity5808 - @entity3450 , passive @entity1310 , spontaneous normotensive @entity9161 , hyperlipidemic @entity2316 ), @entity25536 remained nuclear. This translocation coincided with upregulation of @entity25536 protein levels within the mesangial compartment. Increased @entity25536 expression and subcellular shuttling was dependent on @entity6006 signaling via the mitogen-activated protein kinase pathway because these alterations were prevented by specific PDGF aptamers and the mitogen-activated protein kinase pathway inhibitor @entity5732 . Furthermore, @entity6006 strongly induced @entity25536 expression in vitro. This induction was important because RNAi-dependent knockdown of @entity25536 abolished the mitogenic @entity6006 effect. Taken together, @entity25536 seems to represent a specific and necessary @entity6006 target in mesangioproliferative @entity8 .

title: Y-box protein 1 mediates XXXX effects in mesangioproliferative @entity8 .

entities_list: @entity5808 :: ('MESH:D011691', 'Chemical') :: ['Puromycin']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['glomerular disease']

entities_list: @entity1310 :: ('MESH:D009393', 'Disease') :: ['Heyman nephritis']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy']

entities_list: @entity9161 :: ('MESH:D009400', 'Disease') :: ['nephrosclerosis']

entities_list: @entity3450 :: ('MESH:D009401', 'Disease') :: ['nephrosis']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

answer: @entity6006 :: (5155,Gene) :: ['PDGF-B']


abstract: The objective of this study was to describe recent trends in the management of mild-to-moderate @entity788 and assess @entity1 outcomes. Acute @entity788 has traditionally been managed with open cholecystectomy and intraoperative cholangiography during the initial hospitalization. The popularization of endoscopic retrograde cholangiopancreatography (ERCP) and laparoscopic cholecystectomy has made a reassessment necessary. Two consecutive time periods were retrospectively analyzed: prior to laparoscopic cholecystectomy (prelaparoscopic era [PLE]) and after the diffusion of laparoscopic cholecystectomy (laparoscopic cholectomy era [LCE]). There were 35 @entity1 in the PLE group and 58 in the LCE group. LCE @entity1 waited 37.1 +/- 63 days from admission until cholecystectomy, compared to 9.8 +/- 14.8 days in the PLE group (P = 0.04). @entity660 occurred in 24% of LCE @entity1 and only 6% of PLE @entity1 (P = 0.05), nearly always while they were awaiting cholecystectomy (P = 0.009). @entity1 in either time period who underwent cholecystectomy with intraoperative cholangiography developed less @entity660 than those who underwent ERCP prior to cholecystectomy, with or without sphincterotomy. Delaying the interval from @entity788 to laparoscopic cholecystectomy beyond historical values is associated with a greater risk of recurrent @entity660 , which are not prevented by the use of ERCP. Early cholecys tectomy with intraoperative ductal evaluation is still the approach of choice.

title: Evolving management of mild-to-moderate XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['gallstone pancreatitis', 'pancreatitis']

entities_list: @entity660 :: ('MESH:D010182', 'Disease') :: ['pancreatic-biliary complications', 'biliary-pancreatic complications', 'Biliary-pancreatic complications']

answer: @entity788 :: (MESH:D010190,Disease) :: ['gallstone pancreatitis']


abstract: @entity5910 dehydrogenase from the extreme halophile, @entity51471 , is stable only in highly concentrated solutions of certain salts. Previous work has established that its physiological environment is saturated in @entity4338 ; it remains soluble is saturated @entity1219 or @entity4338 solutions; also it unfolds in solutions containing less than 2.5 M- @entity1219 or - @entity4338 , salt concentrations which are still relatively high. New data show that the structure of this enzyme can be stabilized in a range of high concentrations of @entity1025 or other "salting-in" ions, also with exceptional protein-solvent interactions. "Salting-in" ions, contrary to stabilizing protein structure, usually favour unfolding. These, and most other results concerning the structure, stability and solvent interactions of the protein cannot be understood in terms of the usual effects of salts on protein structure. In this paper, a novel stabilization model is proposed for halophilic @entity5910 dehydrogenase that can account for all observations so far. The model results from experiments on the protein in salt solutions chosen for their different effects on protein stability ( @entity17500 , a strongly "salting-out" agent, and @entity8723 , which is "salting-in"), and previously published data from @entity1219 and @entity4338 solutions (mildly "salting-out"). Enzymic activity and stability measurements were combined with neutron scattering, ultracentrifugation and quasi-elastic light-scattering experiments. The analysis showed that the structure of the protein in solution as well as the dominant stabilization mechanisms were different in different salt solutions in which this enzyme is active. Thus, in molar concentrations of @entity1391 ions, stabilization and hydration are similar to those of non-halophilic soluble proteins, in which the hydrophobic effect dominates. In high concentrations of @entity4338 , @entity1219 or @entity8723 , on the other hand, solution particles are formed in which the protein dimer interacts with large numbers of salt and water molecules (the mass of solvent molecules involved depends on the nature of the salt but it is approximately equivalent to the protein mass). It is proposed that, under these conditions, the hydrophobicity of the protein core is too weak to stabilize the folded structure and the main stabilization mechanism is the formation of co-operative hydrate bonds between the protein and hydrated salt ions. Model predictions are in agreement with all experimental results, such as the different numbers of solvent molecules found in the solution particles formed with different salts, the loss of the exceptional solvent interactions concomitant with unfolding at non-physiological salt concentrations, and the different temperature denaturation curves observed for different salt solutions.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Stabilization of halophilic XXXX dehydrogenase.

entities_list: @entity17500 :: ('MESH:C013216', 'Chemical') :: ['potassium phosphate']

entities_list: @entity5910 :: ('MESH:C030298', 'Chemical') :: ['malate', 'Malate']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity51471 :: ('2238', 'Species') :: ['Halobacterium marismortui']

answer: @entity5910 :: (MESH:C030298,Chemical) :: ['malate']


abstract: The effect of the @entity4621 @entity864 ( @entity865 ) on the release process was studied in presence of different extracellular @entity141 concentrations, in the @entity19 phrenic-diaphragm preparation. Hemidiaphragms were incubated for 2 h at room temperature in the presence or absence of @entity865 . @entity865 increased the basal frequency of miniature end plate potentials (mepp's) in a dose-dependent manner, resulting in a maximal increase of 280% at a concentration of 0.5 microM. An inverse relationship between extracellular @entity141 concentration and @entity865 effect was observed: at high extracellular concentrations of @entity141 the action of @entity865 decreased significatively, while at low @entity141 concentrations the effect of @entity865 was remarkably augmented. The highest effect of @entity865 was obtained when tested in a @entity460 -free medium. @entity865 also increased mepp frequency stimulated by 10 mM K+. As at basal conditions, the effect of @entity865 was higher at lower concentrations of extracellular @entity460 . The results suggest that the effect of stimulation of @entity6164 on neurotransmitter release at the @entity19 neuromuscular junction is not exerted at the level of @entity460 influx to the nerve terminal. Moreover the action of @entity460 and @entity865 seems to be superimposed. The effect of K+ on neurotransmitter release could be explained not only by depolarization of the nerve terminal but by increasing the pool of activable @entity6164 .

title: XXXX role on the effect of phorbol esters on the spontaneous quantal release of neurotransmitter at the @entity19 neuromuscular junction.

entities_list: @entity4621 :: ('CHEBI:37532', 'Chemical') :: ['phorbol ester']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity864 :: ('MESH:C554292|MESH:D013755', 'Chemical') :: ['12-O-tetradecanoylphorbol-13-acetate']

answer: @entity141 :: (CHEBI:29108,Chemical) :: ['Ca2+']


abstract: BACKGROUND AND AIM: Constipation is one of the most common disorders in Western countries and it is known that dietary factors such as a low fiber diet and low caloric intake are associated with this condition. Weight loss can disrupt the intestinal ecosystem resulting in @entity6636 that worsens @entity1142 . The aim of this study was to evaluate the effects of treatment with symbiotic zir @entity1639 ( @entity13854 W11 + @entity1639 Actilight) on chronic @entity1142 in @entity1 undergoing a weight loss diet. METHODS: Our evaluation included the recording of age, gender, weight, height, BMI, physical activity, @entity1142 , diet, therapy compliance and laxative supplies. A hypocaloric diet (1,200/1,400 cal.) was prescribed to all @entity1 , and they were submitted to a physical activity program and received 1 bag of symbiotic zir @entity1639 per day for the entire duration of the study. @entity1 ' follow-up was available for up to 60 days. RESULTS: Two hundred and ninety seven @entity1 (79.4% @entity1 and 18.2% @entity1 , mean age 32.2) were included in the study. The mean baseline BMI was 33.4 +/- 5.6 (range 22.8-56.3 Kg). The improvement of @entity1142 turned out to be associated to age (p < 0.01). @entity1 with a mean age of 35 +/- 12 showed an improvement of @entity1142 . BMI values were not significantly different among the groups of @entity1 with improved, worsened or unchanged @entity1142 . No significative difference was observed among groups due to physical activity. At the follow-up, after 20 days from the beginning of the study, @entity1 that assumed at least 17/20 of the zir @entity1639 bags showed a greater improvement of @entity1142 (p < 0.01) than the remaining @entity1 who assumed less than 17/20 of the zir @entity1639 bags or that didn't assumed any at all. @entity1 that assumed laxatives (at least once a week) showedn to be more frequently associated with a worsening of @entity1142 (p < 0.001). Diet compliance does not seem to influence the course of @entity1142 . CONCLUSION: Our data demonstrate the utility of symbiotics in improving @entity1142 during hypocaloric diet in the treatment of @entity28 .

title: Diet and chronic @entity1142 . Benefits of oral supplementation with symbiotic zir XXXX ( @entity13854 W11 + @entity1639 Actilight).

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity6636 :: ('MESH:D064806', 'Disease') :: ['intestinal dysbiosis']

entities_list: @entity13854 :: ('216816', 'Species') :: ['Bifidobacterium longum']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity1639 :: (2353,Gene) :: ['fos']


abstract: BACKGROUND: Blast injury to the lung is one of the devastating threats facing victims of an explosion. Although the pathogenesis of @entity3614 has been studied, little is known about the long-term effects on lung function in survivors. OBJECTIVE: To examine the pulmonary function of survivors 1 year after sustaining a @entity3614 . DESIGN: Prospective study. SETTING: Pulmonary function test laboratory at Hadassah Medical Center, Jerusalem. @entity1 : Eleven surviving victims of a @entity3614 sustained during a bus terrorist explosion. MEASUREMENTS: Twelve months after the injury, physical examinations, lung function tests, and progressive cardiopulmonary exercise examinations were conducted, and chest radiographs were obtained. RESULTS: The average age was 28 +/- 9.8 years. Most of the victims had @entity1230 in addition to the @entity651 . Ten @entity1 received mechanical ventilation, and 6 @entity1 required chest drainage. All @entity1 were treated in the ICU, with an average stay of 11.8 +/- 9 days. The @entity1 were discharged to their homes or to a rehabilitation center 32.4 +/- 27. 3 days after the explosion. One year later, none had any pulmonary-related complaints. Physical examination of the lungs was normal. Most of the @entity1 demonstrated normal lung function tests and complete resolution of the chest radiograph findings. CONCLUSION: Most @entity1 who survive @entity651 will regain good lung function within a year.

title: Recovery from XXXX : one-year follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity1230 :: ('MESH:D009104', 'Disease') :: ['multiple injuries']

entities_list: @entity3614 :: ('MESH:D001753', 'Disease') :: ['blast injury']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury', 'lung blast injury']

answer: @entity651 :: (MESH:D055370,Disease) :: ['blast lung injury']


abstract: This study explored the effects of a Mindfulness-Based Stress Reduction (MBSR) intervention on reading, attention, and psychological well-being among @entity1 with @entity71 . Various types of @entity5545 exist, characterized by different error types. We examined a question that has not been tested so far: which types of errors (and dyslexias) are affected by MBSR training. To do so, we tested, using an extensive battery of reading tests, whether each @entity1 had @entity5545 , and which errors types s/he makes, and then compared the rate of each error type before and after the MBSR workshop. We used a similar @entity71 : we evaluated the @entity1 ' sustained, selective, executive, and orienting of attention to assess whether they had @entity71 , and if so, which functions were impaired. We then evaluated the effect of MBSR on each of the attention functions. Psychological measures including mindfulness, stress, reflection and rumination, lifesatisfaction, @entity308 , @entity148 , and @entity25 were also evaluated. Nineteen Hebrew-readers completed a 2-month mindfulness workshop. The results showed that whereas reading errors of letter-migrations within and between words and vowelletter errors did not decrease following the workshop, most @entity1 made fewer reading errors in general following the workshop, with a significant reduction of 19% from their original number of errors. This decrease mainly resulted from a decrease in errors that occur due to reading via the sublexical rather than the lexical route. It seems, therefore, that mindfulness helped reading by keeping the readers on the lexical route. This improvement in reading probably resulted from improved sustained attention: the reduction in sublexical reading was significant for the dyslexic @entity1 who also had @entity71 , and there were significant correlations between reduced reading errors and decreases in @entity23 . Following the meditation workshop, the rate of commission errors decreased, indicating decreased @entity23 , and the variation in RTs in the CPT task decreased, indicating improved sustained attention. Significant improvements were obtained in @entity1 ' mindfulness, perceived-stress, rumination, @entity308 , @entity25 . Correlations were also obtained between reading improvement and increased mindfulness following the workshop. Thus, whereas mindfulness training did not affect specific types of errors and did not improve @entity5545 , it did affect the reading of adults with @entity245 and @entity71 , by helping them to stay on the straight path of the lexical route while reading. Thus, the reading improvement induced by mindfulness sheds light on the intricate relation between attention and reading. Mindfulness reduced @entity23 and improved sustained attention, and this, in turn, improved reading of adults with @entity245 and @entity71 , by helping them to read via the straight path of the lexical route.

title: Mindful Reading: Mindfulness Meditation Helps Keep Readers with XXXX and @entity71 on the Lexical Track.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'participant', 'people']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['developmental dyslexia and/or attention deficits', 'ADHD', 'approach to attention disorders', 'attention deficits', 'attention-disorders']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['developmental dyslexia']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['impulsivity']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['state-anxiety, and sleep-disturbances', 'sleep-disturbances']

answer: @entity5545 :: (MESH:D004410,Disease) :: ['Dyslexia']


abstract: @entity27102 produces a @entity3096 -inducible @entity20689 -rich lipopolysaccharide (LPS) that is important for the nodulation of legumes. Many of the genes encoding the rhamnan part of the molecule lie between 87 degrees and 110 degrees of pNGR234a, the symbiotic plasmid of @entity27102 . Computational methods suggest that 5 of the 12 open reading frames (ORFs) within this arc are involved in synthesis (and subsequent polymerization) of @entity10547 . Two others probably play roles in the transport of @entity3363 . To evaluate the function of these ORFs, we mutated a number of them and tested the ability of the mutants to nodulate a variety of legumes. At the same time, changes in the production of surface polysaccharides (particularly the rhamnan O antigen) were examined. Deletion of rmlB to wbgA and mutation in fixF abolished rhamnan synthesis. Mutation of @entity50109 (a member of the @entity855 -binding cassette transporter family) did not abolish production of the @entity20689 -rich LPS but, unexpectedly, the mutant displayed a symbiotic phenotype very similar to that of strains unable to produce the rhamnan O antigen (NGRDeltarmlB-wbgA and NGROmegafixF). At least two @entity3096 -inducible regulatory pathways are involved in synthesis of the rhamnan O antigen. Mutation of either pathway reduces rhamnan production. Coordination of rhamnan synthesis with rhizobial release from infection threads is thus part of the symbiotic interaction.

title: XXXX -inducible modifications to rhamnan O antigens are necessary for @entity27102 -legume symbioses.

entities_list: @entity10547 :: ('CHEBI:62346', 'Chemical') :: ['L-rhamnose']

entities_list: @entity27102 :: ('394', 'Species') :: ['Rhizobium sp. strain NGR234', 'NGR234']

entities_list: @entity3096 :: ('CHEBI:47916', 'Chemical') :: ['flavonoid']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates']

answer: @entity3096 :: (CHEBI:47916,Chemical) :: ['Flavonoid']


abstract: OBJECTIVE: To evaluate the efficacy and safety of a new generation of 2.45-GHz microwave to ablate @entity157 by surgical approach. DESIGN; Case series with prospective follow-up. SETTING: A university teaching hospital in Hong Kong. @entity1 : From March 2009 to January 2011, 26 consecutive @entity1 (19 @entity1 and 7 @entity1 ) with a median age of 63 (range, 49-79) years with @entity157 were recruited. Five (19%) of the @entity1 had recurrent @entity157 after previous treatment. INTERVENTION: Microwave ablation for @entity157 (one @entity5 , n=24; two @entity5 , n=2) using a laparoscopic (n=16) or open approach (n=10). MAIN OUTCOME MEASURES: Operative mortality and morbidity, rate of incomplete ablation, recurrence rate, and survival rate. RESULTS: The median @entity5 diameter was 3.8 cm (range, 2.0-6.0 cm). Complications occurred in five (19%) of the @entity1 ; only one was ablation-related, and there was no operative mortality. One (4%) of the @entity1 experienced incomplete ablation. Recurrent @entity5 were noted in 11 (42%) of the @entity1 (5 were local, 2 were remote, and 4 were multifocal) after a median follow-up of 14 (range, 4-26) months. The failure rate for @entity66 control was 23%, and was 14% if @entity1 with recurrent @entity157 were excluded. All but one @entity1 survived until the time of censorship. The mean survival was 25 (standard deviation, 1) months. CONCLUSION: This new-generation microwave technique is safe and effective for local ablation of @entity157 . It is a valuable treatment option for @entity1 who are not candidates for hepatectomy.

title: Surgical ablation of XXXX with 2.45-GHz microwave: a critical appraisal of treatment outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS', 'men']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma', 'hepatocellular carcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'tumours']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: BACKGROUND: We hypothesized that @entity565 is preceded by a stage of recurrent episodes of wheezing during the first years of life and that inhaled corticosteroid therapy during symptomatic episodes in this early phase may delay progression to persistent wheezing. METHODS: We assigned one-month-old @entity1 to treatment with two-week courses of inhaled @entity4184 (400 mug per day) or placebo, initiated after a three-day episode of wheezing, in this single-center, randomized, double-blind, prospective study of three years' duration. The primary outcome was the number of symptom-free days; key secondary outcomes were the time to discontinuation due to persistent wheezing and safety, as evaluated by height and bone mineral density at the end of the study. RESULTS: We enrolled 411 @entity1 and randomly assigned 294 to receive @entity4184 at a first episode of wheezing. The proportion of symptom-free days was 83 percent in the @entity4184 group and 82 percent in the placebo group (absolute difference, 1 percent; 95 percent confidence interval, -4.8 to 6.9 percent). Twenty-four percent of @entity1 in the @entity4184 group had persistent wheezing, as compared with 21 percent in the placebo group (hazard ratio, 1.22; 95 percent confidence interval, 0.71 to 2.13)--a finding that was unaffected by the presence or absence of @entity483 . The mean duration of the acute episodes was 10 days in both groups and was independent of respiratory viral status. Height and bone mineral density were not affected by treatment. CONCLUSIONS: Intermittent inhaled corticosteroid therapy had no effect on the progression from episodic to persistent wheezing and no short-term benefit during episodes of wheezing in the first three years of life. (ClinicalTrials.gov number, NCT00234390.).

title: Intermittent inhaled corticosteroids in XXXX with episodic wheezing.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'infants']

entities_list: @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis']

answer: @entity1 :: (9606,Species) :: ['infants']


abstract: OBJECTIVE: The role of surgery in the treatment of @entity1 with pulmonary and hepatic metastases from @entity14 has not been delineated. METHODS: Of the 351 @entity1 enrolled in the Metastatic @entity2 Study Group of Japan between June 1988 and June 1996 who underwent thoracotomy for pulmonary metastases from @entity14 , 47 also underwent hepatic resection for @entity3 . The records of these @entity1 were studied. RESULTS: The 47 @entity1 who underwent pulmonary and hepatic resection had a 3-year survival of 36% +/- 8%, a 5-year survival of 31% +/- 8%, and an 8-year survival of 23% +/- 9%. The longest survival was 98 months. This @entity1 was alive without recurrence. There was a significant difference in the cumulative survival of the @entity1 with a solitary pulmonary metastasis and the @entity1 with multiple pulmonary metastases (P =.04). Neither age, sex, location of the @entity5 , maximum diameter of the pulmonary metastases, method of pulmonary resection, number of hepatic metastases, nor method of hepatic resection was correlated with survival. However, 9 of 10 @entity1 who survived 3 years or more after the initial thoracotomy had only one or two hepatic metastases. CONCLUSION: Surgical treatment of a solitary pulmonary metastasis concurrent with or after resection of hepatic metastases from @entity14 may be appropriate if the hepatic metastases are resectable for cure. @entity1 with a solitary pulmonary metastasis and a small number of hepatic metastases are good candidates for resection. Long-term survival can be expected.

title: Surgical treatment for both pulmonary and hepatic metastases from XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung Tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: The cells that express the genes for the fibrillar collagens, types I, II, III and V, during callus development in @entity95 tibial @entity174 healing under stable and unstable mechanical conditions were localized. The fibroblast-like cells in the initial fibrous matrix express types I, III and V collagen mRNAs. Osteoblasts, and osteocytes in the newly formed membranous bone under the periosteum, express the mRNAs for types I, III and V collagens, but osteocytes in the mature trabeculae express none of these mRNAs. Cartilage formation starts at 7 days in calluses forming under unstable mechanical conditions. The differentiating chondrocytes express both types I and II collagen mRNAs, but later they cease expression of type I collagen mRNA. Both types I and II collagens were located in the cartilaginous areas. The @entity1184 chondrocytes express neither type I, nor type II, collagen mRNA. Osteocalcin protein was located in the bone and in some cartilaginous regions. At 21 days, irrespective of the mechanical conditions, the callus consists of a layer of bone; only a few osteoblasts lining the cavities now express type I collagen mRNA. We suggest that osteoprogenitor cells in the periosteal tissue can differentiate into either osteoblasts or chondrocytes and that some cells may exhibit an intermediate phenotype between osteoblasts and chondrocytes for a short period. The finding that @entity1184 chondrocytes do not express type I collagen mRNA suggests that they do not transdifferentiate into osteoblasts during endochondral ossification in @entity174 .

title: The expression of the fibrillar collagen genes during XXXX healing: heterogeneity of the matrices and differentiation of the osteoprogenitor cells.

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture callus']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fracture']


abstract: BACKGROUND: @entity1851 ( @entity1851 ) and @entity12728 ( @entity12728 ) increases with systemic @entity32 and are related to worse survival for @entity0 survivors. This study examines the association between percent body fat and @entity12728 and @entity1851 and the potential interaction with NSAID use and weight change. METHODS: @entity1 included 134 @entity0 survivors from the Health, Eating, Activity, and Lifestyle Study. Body fat percentage, measured with Dual Energy X-ray Absorptiometer (DEXA), and circulating levels of @entity1851 and @entity12728 were obtained 30   months after @entity0 . RESULTS: Circulating concentrations of @entity1851 and @entity12728 were associated with increased adiposity as measured by DEXA after adjustment for age at 24-months, race/ethnicity, dietary energy intake, weight change, and NSAID use. Survivors with higher body fat >= 35% had significantly higher concentrations of @entity1851 (2.01   mg/l vs. 0.85   mg/l) and @entity12728 (6.21   mg/l vs. 4.21   mg/l) compared to @entity28 (body fat   <   35%). @entity1 who had gained more than 5% of their body weight since @entity0 had non-statistically significant higher geometric mean levels of @entity1851 and @entity12728 . Mean levels of @entity1851 and @entity12728 were higher among @entity28 @entity1 who were non-users of NSAIDs compared to current users; the association with @entity12728 reached statistical significance (Mean @entity12728   =   7.24, 95%CI 6.13-8.56 for non-NSAID; vs. 4.87; 95%CI 3.95-6.0 for NSAID users respectively). CONCLUSIONS: @entity0 survivors with higher body fat had higher mean concentrations of @entity1851 and @entity12728 than @entity1 with lower body fat. Further assessment of NSAID use and weight control in reducing circulating inflammatory markers among survivors may be worthwhile to investigate in randomized intervention trials as higher inflammatory markers are associated with worse survival.

title: DEXA measures of body fat percentage and acute phase proteins among XXXX survivors: a cross-sectional analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Women', 'Participants']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer diagnosis', 'breast cancer', 'non-Hispanic white and Hispanic breast cancer']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'non-obese']

entities_list: @entity12728 :: ('6288', 'Gene') :: ['Serum amyloid A protein', 'SAA']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: @entity454 ( @entity454 ) is associated with increased propensity to infections, diminished response to vaccination, impaired cell-mediated immunity, and reduced @entity404 +/ @entity405 + T-lymphocyte ratio. Four subsets of @entity404 + and @entity405 + T cells have been recently identified: na  ve cells (as yet uncommitted), central memory (CM) cells (previously programmed), and CD45RA-positive and CD45RA-negative effector memory (EM) cells (programmed to perform specific effector functions). The effect of @entity454 on subpopulations of T lymphocytes is unclear and was studied here. Twenty-one hemodialysis @entity1 and 21 age-matched controls were studied. Pre- and post-dialysis blood samples were obtained and analyzed by three-color flow cytometry. @entity404 +/ @entity405 + ratio and the numbers of the na  ve and CM @entity404 + and @entity405 + T cells were significantly reduced, whereas the numbers of EM @entity404 + and @entity405 + T cells were unchanged in the @entity454 group. The reduction of the na  ve and CM T-cell counts in the @entity454 group was associated with increased apoptosis of these cells. Negative correlations were found between severity of @entity2629 , oxidative stress, and @entity2265 with the number of na  ve T cells. Comparison of @entity6 with non- @entity6 @entity454 @entity1 revealed higher numbers of total @entity405 + cells and EM @entity405 + T cells in the @entity6 group. Dialysis did not significantly change the na  ve and CM @entity404 + or @entity405 + cell counts, but significantly lowered @entity405 + EM cell count. Thus, @entity454 results in increased apoptosis and diminished populations of na  ve and CM T lymphocytes. This phenomenon may, in part, contribute to the impaired immune response in this population.

title: Na  ve and central memory T-cell lymphopenia in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD', 'End-stage renal disease']

answer: @entity454 :: (MESH:D007676,Disease) :: ['end-stage renal disease']


abstract: BACKGROUND: In our previously published work dealing with antibody-mediated (vascular) rejection (AMR), we defined patterns of rejection (AMR and cellular rejection [CR]) based on a review of biopsy diagnoses taken in the first 6 to 12 weeks post-transplant. We have shown the significance of these pattern designations in relation to @entity1 and allograft outcome in five outcome analyses. The current retrospective analysis was done to determine whether our previous criteria for pattern designations provided the greatest degree of discrimination between AMR and CR. METHODS: Six hundred sixty-five @entity1 from the U.T.A.H. Cardiac Transplant Program were included in our study. @entity1 induced with OKT3 immunosuppression were excluded. We analyzed the relationship of a number of either AMR or CR episodes to @entity65 . We constructed Kaplan-Meier survival curves to assess the @entity44460 or CR episodes on @entity65 . RESULTS: Three or more episodes of AMR resulted in a statistically significant increase in @entity65 . By contrast, CR episodes did not increase the risk of @entity65 . CONCLUSIONS: Based on our findings, we believe that clinical trials should be designed to test treatments based on predominant rejection patterns and that end-points for trials should be defined by number of biopsies positive for either CR or AMR. This approach may lead to improved @entity1 and allograft survival.

title: Impact of repetitive episodes of antibody-mediated or cellular rejection on XXXX in cardiac transplant recipients: defining rejection patterns.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality']

entities_list: @entity44460 :: ('MESH:C565965', 'Disease') :: ['impact of incremental numbers of AMR']

answer: @entity65 :: (MESH:D002318,Disease) :: ['cardiovascular mortality']


abstract: We investigated the effect of @entity2049 on @entity410 associated with mild @entity1902 . Sixteen @entity1 and young @entity1 (aged 9 months to 3 years) who experienced repetitive @entity410 associated with mild @entity1902 were admitted to our hospital. We treated the sixteen affected @entity1 with 5 mg/kg of @entity2049 once per day until the @entity294 had stopped. Thirteen of the sixteen @entity1 were subjected to intravenous and/or suppository administration of @entity3175 (0.3-0.5 mg/kg/time), and one @entity1 suppository administration of 0.5 mg/kg @entity3175 and 5.7 mg/kg @entity109 before the administration of @entity2049 . In all @entity1 who were given @entity3175 and/or @entity109 , the @entity410 recurred after the administration of these medicines. The @entity410 occurred 2 to 8 times (mean, 4.1 times) before the administration of @entity2049 . Fifteen of the sixteen @entity1 had no @entity410 after the administration of @entity2049 . One @entity1 had one @entity410 15 min after the administration of @entity2049 . All @entity1 were treated with 5 mg/kg of @entity2049 once per day until the @entity294 had stopped, i.e. for 2 to 9 days (mean, 6.4 days). Low dose therapy with @entity2049 once per day is thus effective for @entity410 associated with mild @entity1902 .

title: [Low-dose therapy with @entity2049 for @entity410 associated with mild XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'infants']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures', 'convulsion', 'convulsions']

entities_list: @entity3175 :: ('MESH:D003975', 'Chemical') :: ['diazepam']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity1902 :: ('MESH:D005759', 'Disease') :: ['gastroenteritis']

entities_list: @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbital']

entities_list: @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']

answer: @entity1902 :: (MESH:D005759,Disease) :: ['gastroenteritis']


abstract: PURPOSE: To retrospectively compare the clinical outcome for @entity5 @entity1 treated with @entity1168 ( @entity1168 ) vs. low-dose-rate (LDR) brachytherapy. METHODS AND MATERIALS: One hundred ninety-one LDR @entity1 were treated from 1977 to 1988 and compared to 173 @entity1168 @entity1 treated from 1989 to 1996. @entity1 of similar stage and @entity5 volumes were treated with identical external beam fractionation schedules. Brachytherapy was given in either 1 or 2 LDR implants for the earlier @entity1 cohort, and 5 @entity1168 implants for the latter cohort. For both @entity1 groups, Point A received a minimum total dose of 80 Gy. The linear-quadratic formula was used to calculate the LDR dose-equivalent contribution to Point A for the @entity1168 treatments. The primary endpoints assessed were survival, pelvic control, relapse-free survival, and distant metastases. Endpoints were estimated using the Kaplan-Meier method. Comparisons between treatment groups were performed using the log-rank test and Cox proportional hazards models. RESULTS: The median follow-up was 65 months (2 to 208 months) in the LDR group and 22 months (1 to 85 months) in the @entity1168 group. For all stages combined there was no difference in survival, pelvic control, relapse-free survival, or distant metastases between LDR and @entity1168 @entity1 . For Stage IB and II @entity1168 @entity1 , the pelvic control rates were 85% and 80% with survival rates of 86% and 65% at 3 years, respectively. In the LDR group, Stage IB and II @entity1 had 91% and 78% pelvic control rates, with 82% and 58% survival rates at 3 years, respectively. No difference was seen in survival or pelvic control for bulky Stage I and II @entity1 combined (>5 cm). Pelvic control at 3 years was 44% ( @entity1168 ) versus 75% (LDR) for Stage IIIB @entity1 (p = 0.002). This difference in pelvic control was associated with a lower survival rate in the Stage IIIB @entity1168 versus LDR population (33% versus 58%, p = 0.004). The only major difference, with regard to @entity1 characteristics, between the Stage IIIB @entity1 was the incidence of @entity3041 in the @entity1168 vs. LDR group--28% vs. 12%, respectively (p = 0.05). For Stage IIIB @entity1 treated with @entity1168 , our analysis suggested that pelvic control rates improved when the first brachytherapy insertion was performed after the majority of external beam radiotherapy had been delivered. CONCLUSION: Similar outcome was observed for Stage IB and II @entity1 treated with either @entity1168 or LDR brachytherapy-regardless of @entity5 volume. However, poorer survival and pelvic control rates were observed for Stage IIIB @entity1 treated with @entity1168 brachytherapy. If @entity1168 is used for Stage IIIB @entity1 , our results suggest the majority of external beam radiotherapy should be delivered prior to initiating the brachytherapy to allow for adequate @entity5 regression. @entity1168 brachytherapy is more convenient for @entity1 , decreases the radiation exposure for health care workers, and should be considered a standard therapy for @entity1 with @entity5 .

title: High-dose-rate versus low-dose-rate brachytherapy in the treatment of XXXX : analysis of @entity5 recurrence--the University of Wisconsin experience.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer', 'Stage I or II cervical cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high-dose-rate']

entities_list: @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: OBJECTIVE: The aim of this study was to assess the efficacy of adalimumab in @entity1 with active non-infectious @entity1596 in three different centres. METHODS: In a retrospective study we identified @entity1 from our databases who were treated with adalimumab. The composite outcome measure for efficacy included reduction of macular @entity4 by optic coherence tomography, visual acuity, anterior chamber cells, reduction of frequency of flares and reduction of @entity229 dose during the treatment. At least one of the criteria had to be improved and none worsened to declare treatment as effective. RESULTS: 60 @entity1 with an average age of 37.3 years (range 4-71 years) were treated with adalimumab over an average follow-up period of 87.9 weeks (range 12-222 weeks). The indication for treatment was in 41 (68.3%) @entity1 the activity of both @entity1596 and @entity262 and in 19 (31.7%) @entity1 @entity1596 activity only. 15 (25%) @entity1 were treated before with etanercept and 10 (16.7%) @entity1 with infliximab. 49 out of 60 (81.7%) @entity1 improved, while the other 11 (18.3%) @entity1 did not meet improvement criteria and were given additional or alternative immunosuppressive treatment. At the last follow-up, 47 (78.3%) @entity1 were still on adalimumab treatment. 13 (21.6%) @entity1 stopped adalimumab treatment, due to inefficacy in eight, another three @entity1 due to side effects (liver enzyme elevation and @entity6690 ), one @entity1 due to pregnancy and one @entity1 died. CONCLUSIONS: This large retrospective case series showed that adalimumab is effective in up to 80% of @entity1 with @entity1596 .

title: A three-centre experience with adalimumab for the treatment of non-infectious XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease']

entities_list: @entity6690 :: ('MESH:D005667', 'Disease') :: ['furunculosis']

answer: @entity1596 :: (MESH:D014605,Disease) :: ['uveitis']


abstract: We conducted a case-control study in China to clarify the association between @entity20319 - @entity20322 polymorphism and @entity157 risk. A total of 150 cases and 158 controls were selected from the the Affiliated Hospital of Qingdao University from May 2008 to May 2010. @entity20319 - @entity20322 polymorphism was based upon duplex polymerase-chain-reaction with the confronting-two-pair primer (PCR-CTPP) method. All analyses were performed using the STATA statistical package. A significantly increased risk was associated with the @entity534 / @entity7647 genotype (adjusted OR 1.78, 95%CI=1.13-2.79) compared with genotype @entity534 / @entity534 . In contrast, the @entity7647 / @entity7647 genotype had non-significant increased risk of @entity157 with adjusted OR (95%CI) of 1.69 (0.93-2.66). A significant association was found between positive HBsAg and @entity534 / @entity7647 , with an OR of 3.43 (95% CI=1.45-8.13). @entity1 carrying @entity7647 / @entity7647 genotypes showed significantly lower median survival than @entity534 / @entity534 genotypes (HR=1.38, 95% CI=1.04-1.84). Further Kaplan-Meier analysis showed decreased median survival in @entity534 / @entity7647 + @entity7647 / @entity7647 genotype carriers in comparison to @entity534 / @entity534 carriers (HR=1.33, 95% CI=1.02-1.76). In conclusion, we observed that @entity20319 - @entity48513 polymorphism is associated with susceptibility to @entity157 , and @entity20319 @entity7647 allele genotype showed significant prognostic associations.

title: Evaluation of DNA repair gene XXXX polymorphism in prediction and prognosis of @entity157 risk.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity20322 :: ('p|SUB|R|399|Q', 'ProteinMutation') :: ['Arg399Gln']

entities_list: @entity48513 :: ('p|SUB|R|399|CLN', 'ProteinMutation') :: ['Arg399Cln']

answer: @entity20319 :: (7515,Gene) :: ['XRCC1']


abstract: Twenty-three @entity1 with metastatic @entity0 were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure. The durability of the remissions was observed by discontinuing therapy after 3 cycles in complete remission or after 6 cycles of treatment, whichever was longer. In 13 @entity1 consolidation radiation therapy to the pre-treatment sites of disease was administered after discontinuing systemic therapy. Each 28 day cycle of the drug regimen consisted of pulses of @entity632 , @entity1891 , @entity14954 , @entity229 , @entity1499 with leukovorin rescue, @entity11558 , @entity1732 (discontinued after entry #17), @entity6240 , and @entity440 . Eighteen of the 23 @entity1 achieved complete remissions (78%) and 3 had partial remissions. The median times to treatment failure and survival were, respectively, 12.3 and 19.4 mos. The times for complete remission @entity1 were, respectively, 13.5 and 23.9 mos. Consolidation radiotherapy at greater than or equal to 40 Gy to drug induced pre-study sites of complete remission was associated with first relapses at pre-study sites in 5/30 (17%) instances, compared to 21/35 (60%) in sites not receiving radiotherapy. Side-effects were commensurate with the intensity of the treatment program and are detailed in the text. Although the achievement of a high complete remission rate is promising, the failure to extend their duration beyond that of historical data suggests that additional conceptual and therapeutic approaches need to be explored.

title: Short term high density systemic therapy for metastatic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin']

entities_list: @entity14954 :: ('MESH:D008936', 'Chemical') :: ['dibromodulcitol']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity6240 :: ('MESH:D005474', 'Chemical') :: ['fluoxymesterone']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity11558 :: ('MESH:D006585', 'Chemical') :: ['hexamethylmelamine']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: BACKGROUND: @entity9808 ( @entity9808 ), a noninvasive technique for stimulation of the brain, has recently been suggested to be effective for the treatment of @entity308 . We conducted a double-blind, placebo-controlled study to assess the efficacy of slow repetitive @entity9808 (rTMS) in @entity1 with @entity308 . METHODS: Seventy @entity1 with @entity308 (53 @entity1 , 17 @entity1 ; mean age, 58.7 years; SD, 17.2 years) were randomly assigned to receive rTMS or sham rTMS in a double-blind design. Treatment was administered in 10 daily sessions during a 2-week period. Severity of @entity308 was blindly assessed before, during, and after completion of the treatment protocol. RESULTS: All @entity1 completed the first week of treatment and 67 completed the entire protocol. @entity1 who received rTMS had a significantly greater improvement in @entity308 scores compared with those who received sham treatment. At the end of 2 weeks, 17 of 35 @entity1 in the rTMS group, but only 8 of 32 in the sham-treated group, had an improvement of greater than 50% in their @entity308 ratings. CONCLUSIONS: This controlled study provides evidence for the short-term efficacy of slow rTMS in @entity1 with recurrent @entity308 . Additional studies will be necessary to assess the efficacy of rTMS as compared with electroconvulsive therapy as well as the long-term outcome of this treatment in @entity308 and possibly other @entity146 .

title: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in XXXX : a double-blind controlled study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity9808 :: ('MESH:C536917', 'Disease') :: ['TMS', 'Transcranial magnetic stimulation']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'major depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders']

answer: @entity308 :: (MESH:D003866,Disease) :: ['major depression']


abstract: We have developed a personal computer-based system designed for automated metabolic profiling of urinary organic acids by gas chromatography-mass spectrometry (GC/ @entity15 ) and data interpretation for @entity347 screening. For the automated profiling, we compiled retention indices, two target ions and their intensity ratio for 126 urinary metabolites. Metabolites above the cut-off values were flagged as abnormal compounds. The data interpretation was based on combination of the flagged metabolites. Diagnostic or index metabolites were categorized into three groups, "AND," "OR" and "NO," and compiled for @entity74 to improve the specificity of the diagnosis. Groups "AND" and "OR" comprised essential and optional compounds, respectively, which and both to reach a specific diagnosis. Group "NO" comprised metabolites that must be absent to make a definite diagnosis. We tested this system by analyzing urine specimens from 48 @entity1 previously diagnosed as having @entity347 . In all cases, the diagnostic metabolites were identified and each correct diagnosis could be found among the possible diseases suggested by the system. Hence, with this simplified automated system, more @entity1 will be able to participate extensively in any screening programs using GC/ @entity15 .

title: Automated metabolic profiling and interpretation of GC/ @entity15 data for XXXX screening: a personal computer-based system.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['each disorder']

entities_list: @entity347 :: ('MESH:D019965', 'Disease') :: ['organic acidemias', 'organic acidemia']

answer: @entity347 :: (MESH:D019965,Disease) :: ['organic acidemia']


abstract: The protection of @entity1 and domestic animals against @entity281 remains a major goal, especially in light of developing of drug resistant strains in many parasite species. "Classic" vaccines are based on @entity536 . Although such vaccines are effective in confering host immunity against several protozoan ( @entity7843 , giardiosis, toxoplasmosis) diseases and one helminth (dictyocaulosis) they are very unstable and expensive. Recombinant techniques enable to obtain protective antigens quickly and in considerable quantities, cultivating of the bacteria and purification of the recombinant protein is less expensive than the maintenance of host animals and isolation of the protective antigens from harvested @entity4801 . Moreover, the cloned protective antigens may be deprived of epitopes responsible for immunopathology. However, at present only one anti-parasite recombinant protein vaccine is commercially available (TickGARD). Such a situation may result from that many protective parasitic antigens cannot be expressed in bacteria or @entity375 in anative from. DNA vaccines present many advantages over protein ones. Firstly, the antigenic proteins synthesised within the host cell possess an appropriate molecular structure and undergo a post-translational modifications specific for a native protein. The next advantage of DNA vaccines is that DNA is easier to handle and more resistant than proteins to temperature changes. DNA vaccines are likely to induce novel mechanisms of immune response, which may be beneficial in case of parasitic invasions. Costs of DNA vaccines are comparable, and may be even lower, in comparison to recombinant protein vaccines. The main obstacle preventing the use of DNA vaccines is still lack of the complete knowledge concerning mechanisms of their action. Vaccines based on transgenic plants (=edible vaccines), expressing the protective parasitic antigens, present another promising approach in research on anti-parasitic vaccines. Such vaccines may be of special importance in prevention of @entity281 with @entity344 .

title: [The new generations of vaccines against XXXX ].

entities_list: @entity7843 :: ('MESH:D003048', 'Disease') :: ['coccidiosis']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal parasites']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['parasitic infections', 'infections']

entities_list: @entity536 :: ('MESH:C538265', 'Disease') :: ['attenuated infective stages of protozoan and helminth parasites']

entities_list: @entity4801 :: ('MESH:D010272', 'Disease') :: ['parasites']

answer: @entity4801 :: (MESH:D010272,Disease) :: ['parasites']